Kyte Group

[Kyte Group @GroupKyte]

Thanks to "DM Arena" for organizing the Post ASCO meeting this week. It was a pleasure to contribute.
https://t.co/PBUxEhpS0y

@DagensMedisin @dagensmedicin @Oslounivsykehus @fkbmatrix @OsloCancer

[Kyte Group @GroupKyte]

Congratulations to @KjetilTasken for receiving the Annual Excellent Researcher Award from @Oslounivsykehus today – well deserved!

[Kyte Group @GroupKyte]

Thrilled to announce our paper "Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform" has been chosen as an Editor’s Choice Article for 2022-2023!
Thanks to our dedicated team and contributors.

[Cancers MDPI @Cancers_MDPI]

📣 Check out Editor’s Choice Articles from 2022–2023 Related to Methods and Technologies Development

🤗 Find more details here: https://t.co/QtsH8MfXfT

[Kyte Group @GroupKyte]

Delighted to share that our article "Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation" has been published npj Breast Cancer
https://t.co/LpwVm4hvIL

[Kreftforskning_ous @Cancertrial_ous]

Vi gratulerer Johanna Olweus & The Matchmakers som er en av fem vinnere av Cancer Grand Challenges og får 250 millioner til å løse en av de store utfordringene unnen kreftforskning https://t.co/x0YrVZJZKJ

[Kyte Group @GroupKyte]

On February 9th, Andreas Hagen Røssevold triumphantly completed his Ph.D. defense on "Immunotherapy and immunological biomarkers in breast cancer" at the OUH. For more details on his groundbreaking research, read his recent publications on @NatureMedicine and ​​@jitcancer.

[Vessela Kristensen @Vesselinka]

Congratulations to Andreas Røssevold MD, PhD with his fantastic PhD defence and discussion over the outcomes of the Alice snd Icon trials @GroupKyte @UniOslo_MED @RESCUER2020

[Kyte Group @GroupKyte]

Excited to announce our pioneer ICON clinical trial study published in @jitcancer. Thanks to our patients, collaborators, and funders (BMS, Health Region South East, Pink Ribbon/Norwegian Cancer Society). #MATRIX #Oncodistinct #JulesBordet https://t.co/8iOKywIrNL

[Kyte Group @GroupKyte]

🔬 Exciting Postdoc Opportunity
🔍 Join us in advancing Machine Learning for Cancer Immunotherapy.
We're looking for a talented Postdoctoral Researcher to join our team.

Explore the details and apply here:
https://t.co/1HJA8D9RLd

[Kyte Group @GroupKyte]

Big thanks to the Norwegian Society of Immunology for honoring our ALICE article (Nat Med) with the NSI 2023 Research Prize! 🏆
Gratitude to the Norwegian Cancer Society/Pink Ribbon, Heath Region South East, Roche, ALICE team, study sites, and above all, our resilient patients.

[Kyte Group @GroupKyte]

https://t.co/K4yHQNlsdO

[Kyte Group @GroupKyte]

Exciting Postdoc Opportunity in CAR T cell!
🌐 We're seeking a talented researcher to join our team at the Institute for Cancer Research, Oslo University Hospital (OUH).
Explore cutting-edge innovative projects and contribute to groundbreaking research.
https://t.co/cSMuL4qKrI

[Kyte Group @GroupKyte]

We are honored and grateful to the Cancer Society & Pink Ribbon for awarding their Open Call grant to our project on personalised breast cancer immunotherapy - look forward to getting on with the work!

[Kyte Group @GroupKyte]

Åslaug Helland fikk i dag overrakt Kong Olav´s kreftforskningspris av Kong Harald i Universitetets Aula. Gratulerer, Åslaug - vel fortjent!
@HellandAslaug

[Kyte Group @GroupKyte]

International Day of Immunology!
Jon Amund Kyte giving a talk about immunotherapy against breast cancer at the Norwegian Society for Immunology (NSI).
@AmundJon @NSImmun

[Kyte Group @GroupKyte]

Congratulations to Professor Åslaug Helland with King Olav V's Prize for Cancer Research!!
Very well deserved! We look forward to working together with Åslaug to further advance cancer research, within and beyond the new national center MATRIX.
@HellandAslaug

[Kyte Group @GroupKyte]

We are looking for a highly motivated and skilled "Special engineer" in cancer immunotherapy.

Check out the ad if you are interested in joining a dynamic cutting-edge research group.

https://t.co/67FrQH9wdy

[Kyte Group @GroupKyte]

A new method of treating aggressive breast cancer offers hope for more patients.
Norwegian researchers receive international attention for their findings.
https://t.co/jH1Pn7InMZ

[Nature Medicine @NatureMedicine]

In patients with metastatic triple-negative #BreastCancer, atezolizumab + anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease #SABCS22 @andreashr @GroupKyte @AmundJon @Oslounivsykehus @UniOslo_MED #BCsm https://t.co/vJwpj3qssQ

[Kyte Group @GroupKyte]

We are delighted to share that the first results from the ALICE-trial were today published in Nature Medicine and presented at San Antonio Breast Cancer Symposium. Thanks to the patients and the study teams. Look forward to further work.
https://t.co/Ds12UlBNP6